What's Happening?
The U.S. Food and Drug Administration (FDA) approved Elanco Animal Health's drug Experior in 2018, despite internal scientific concerns regarding its impact on cattle health. Experior, which contains an active ingredient from a class of growth-promoting
pharmaceuticals, was approved not for growth but for its ability to moderately reduce ammonia emissions from cattle. However, studies submitted by Elanco showed increased lameness and bloat, a condition that can lead to suffocation and death, in cattle receiving the highest doses of Experior. Post-approval, sales of Experior boomed, generating over $200 million in 2025, with more than half of U.S. feedlot cattle now receiving the drug. Feedlot veterinarians are reporting similar health issues, including bloat-related deaths and lameness, mirroring the concerns raised during the initial review. The FDA has received 75 adverse event reports involving lubabegron, Experior's active ingredient, with 59 linked to death, including one report documenting 229 unexpected deaths in a single feedlot.
Why It's Important?
The approval and widespread use of Experior highlight significant concerns regarding the FDA's regulatory processes and the influence of pharmaceutical companies and the livestock industry. The drug's approval for environmental benefits, despite evidence of adverse health effects in cattle, raises questions about the agency's priorities and the potential for industry interests to shape policy. The increase in health problems among heavier cattle, as documented by the U.S. Department of Agriculture, suggests a broader issue of animal welfare in the pursuit of increased weight gain and profit. The Animal Drug User Fee Act (ADUFA), which allows drugmakers to fund FDA reviews, creates a potential conflict of interest, with critics arguing it prioritizes speed of approval over public health and safety. This situation also brings to light the role of academic scientists in promoting industry products, often without disclosing financial ties, further blurring the lines between independent research and corporate interests.
What's Next?
The FDA is currently evaluating the adverse event reports associated with lubabegron through its post-market review processes. The reauthorization of the Animal Drug User Fee Act (ADUFA) is under negotiation, and discussions are ongoing regarding the potential conflicts of interest it creates. Stakeholders like the Food Animal Concerns Trust are advocating for changes to prioritize public health over rapid drug approvals. The Animal Legal Defense Fund previously filed a lawsuit questioning the drug's safety for animals and consumers, though it was ruled in favor of the FDA and no appeal is currently planned. Future developments may include increased scrutiny of drug approval processes, potential changes to ADUFA, and ongoing monitoring of animal health in feedlots using Experior. The debate over the safety of consuming beef from cattle treated with Experior, particularly concerning potential residues and their effects on vulnerable populations, is also likely to continue.
Beyond the Headlines
The Experior case exposes deeper ethical and systemic issues within the U.S. agricultural and regulatory landscape. The drug's marketing for environmental benefits, while allegedly contributing to animal health problems and increased weight gain, underscores a complex interplay between environmental claims, economic incentives, and animal welfare. The lack of stringent funding disclosure requirements for animal pharmaceuticals, unlike human medicine, raises concerns about transparency and potential biases in research and promotion. This situation also reflects a broader societal challenge in balancing agricultural productivity and economic gain with ethical considerations for animal treatment and potential long-term impacts on the food supply. The push for heavier cattle, facilitated by drugs like Experior, may be pushing animals beyond their physiological limits, leading to increased suffering and raising fundamental questions about the sustainability and ethics of current industrial farming practices.
